Prevalence of IgG anti-HAV in patients with chronic hepatitis B and in the general healthy population in Korea
1
조회
0
다운로드
0
인용
0
참고문헌
초록
Background/Aims: Few studies have investigated hepatitis A virus (HAV) seroepidemiology in Koreans with chronic liver disease (CLD). This study compared the prevalence of IgG anti-HAV between the general healthy population and patients with hepatitis B virus-related CLD (HBV-CLD), with the aim of identifying predictors of HAV prior exposure. Methods: In total, 1,319 patients were recruited between June 2008 and April 2010. All patients were tested for IgG anti-HAV, hepatitis B surface antigen (HBsAg), and antibodies to hepatitis C virus. The patients were divided into the general healthy population group and the HBV-CLD group based on the presence of HBsAg. The seroprevalence of IgG anti-HAV was compared between these two groups. Results: The age-standardized seroprevalence rates of IgG anti-HAV in the general healthy population and patients with HBV-CLD were 52.5% and 49.1%, respectively. The age-stratified IgG anti-HAV seroprevalence rates for ages ≤19, 20-29, 30-39, 40-49, 50-59, and ≥60 years were 14.3%, 11.2%, 45.5%, 90.5%, 97.6% and 98.3%, respectively, in the general healthy population, and 0%, 9.8%, 46.3%, 91.1%, 97.7%, and 100% in the HBV-CLD group. In multivariate analysis, age (<30 vs. 30-59 years: OR=19.339, 95% CI=12.504-29.911, P<0.001; <30 vs. ≥60 years: OR=1060.5, 95% CI=142.233-7907.964, P<0.001) and advanced status of HBV-CLD (OR=19.180, 95% CI=4.550-80.856, P<0.001) were independent predictors of HAV prior exposure. Conclusions: The seroprevalence of IgG anti-HAV did not differ significantly between the general-healthy-population and HBV-CLD groups. An HAV vaccination strategy might be warranted in people younger than 35 years, especially in patients with HBV-CLD.
Abstract
Background/Aims: Few studies have investigated hepatitis A virus (HAV) seroepidemiology in Koreans with chronic liver disease (CLD). This study compared the prevalence of IgG anti-HAV between the general healthy population and patients with hepatitis B virus-related CLD (HBV-CLD), with the aim of identifying predictors of HAV prior exposure. Methods: In total, 1,319 patients were recruited between June 2008 and April 2010. All patients were tested for IgG anti-HAV, hepatitis B surface antigen (HBsAg), and antibodies to hepatitis C virus. The patients were divided into the general healthy population group and the HBV-CLD group based on the presence of HBsAg. The seroprevalence of IgG anti-HAV was compared between these two groups. Results: The age-standardized seroprevalence rates of IgG anti-HAV in the general healthy population and patients with HBV-CLD were 52.5% and 49.1%, respectively. The age-stratified IgG anti-HAV seroprevalence rates for ages ≤19, 20-29, 30-39, 40-49, 50-59, and ≥60 years were 14.3%, 11.2%, 45.5%, 90.5%, 97.6% and 98.3%, respectively, in the general healthy population, and 0%, 9.8%, 46.3%, 91.1%, 97.7%, and 100% in the HBV-CLD group. In multivariate analysis, age (<30 vs. 30-59 years: OR=19.339, 95% CI=12.504-29.911, P<0.001; <30 vs. ≥60 years: OR=1060.5, 95% CI=142.233-7907.964, P<0.001) and advanced status of HBV-CLD (OR=19.180, 95% CI=4.550-80.856, P<0.001) were independent predictors of HAV prior exposure. Conclusions: The seroprevalence of IgG anti-HAV did not differ significantly between the general-healthy-population and HBV-CLD groups. An HAV vaccination strategy might be warranted in people younger than 35 years, especially in patients with HBV-CLD.
참고문헌 (27)
- Lemon SM, "Type A viral hepatitis. New developments in an old disease", N Engl J Med, 313, pp.1059~1067 (1985)
- Jung YK, "Epidemiology and clinical features of acute hepatitis A: from the domestic perspective", Korean J Hepatol, 15, pp.438~445 (2009)
- Kwon SY, "Current status of liver diseases in Korea: hepatitis A", Korean J Hepatol, 15(6), pp.7~12 (2009)
- 정숙향, "국내 A형간염의 현황과 백신 적응증", 대한소화기학회지, 51(6), pp.331~337 (2008), 대한소화기학회
- Prospective study about natural history of chronic hepatitis B in Korea in The status and development of new therapy and prevention about chronic hepatitis B and C in Korea, "Lee CH", Department of health and welfare, 28~62, pp.Final report about intensive cooperative study (HMP-99-M-01-0008) (2002)
- Kim do Y, "Anti-hepatitis A virus seroprevalence among patients with chronic viral liver disease in Korea", Eur J Gastroenterol Hepatol, 19, pp.923~926 (2007)
- Hyun Joo Song, "Emerging Need for Vaccination against Hepatitis A Virus in Patients with Chronic Liver Disease in Korea", Journal of Korean Medical Science, 22(2), pp.218~222 (2007), 대한의학회
- Lok AS, "Chronic hepatitis B", Hepatology, 45, pp.507~539 (2007)
- Bruix J, "Management of Hepatocellular Carcinoma", Hepatology, 42, pp.1208~1236 (2005)
- Kim JY, "Seroepilemiology of Type A and Type B Hepatitis in Seoul Area", The Korean Journal of Medicine, 25, pp.19~27 (1982)
- Chae HB, "Current status of liver diseases in Korea: hepatitis B", Korean J Hepatol, 15(6), pp.13~24 (2009)
- Pramoolsinsap C, "Acute hepatitis A and acquired immunity to hepatitis A virus in hepatitis B virus (HBV) carriers and in HBV- or hepatitis C virus-related chronic liver diseases in Thailand", J Viral Hepat, 7(1), pp.11~12 (2000)
- Chu CM, "Increased incidence of fulminant hepatic failure in previously unrecognized HBsAg carriers with acute hepatitis independent of etiology", Infection, 33, pp.136~139 (2005)
- Keeffe EB, "Is hepatitis A more severe in patients with chronic hepatitis B and other chronic liver diseases?", Am J Gastroenterol, 90, pp.201~205 (1995)
- 김주일, "Factors influencing the severity of acute viral hepatitis A", The Korean Journal of Hepatology, 16(3), pp.295~300 (2010), 대한간학회
- Hindman SH, "Simultaneous infection with type A and B hepatitis viruses", Am J Epidemiol, 105, pp.135~139 (1977)
- Saab S, "Seroepidemiology of hepatitis A in patients with chronic liver disease", J Viral Hepat, 12, pp.101~105 (2005)
- Cho HJ, "Prevalence of hepatitis a virus antibody in paitients with chronic liver disease", Korean J Hepatol, 16(3), pp.S196~ (2010)
- Kim JH, "Recent Epidemiological Status and Vaccination of Hepatitis A in Korea", J Korean Med Assoc, 51, pp.110~118 (2008)
- 송영봉, "한국인 건강검진자에서 연령 특이적 A형간염바이러스 항체 혈청 양성률대한간학회지 제 13 권 제 1 호 2007 ; 27-33", The Korean Journal of Hepatology, 13(1), pp.27~33 (2007), 대한간학회
- Lee D, "Hepatitis a in Korea: epidemiological shift and call for vaccine strategy", Intervirology, 51, pp.70~74 (2008)
- 김태엽, "서울과 경기지역 두 병원의 최근 A형간염 항체 양성률에 대한 비교 조사", The Korean Journal of Hepatology, 13(3), pp.363~369 (2007), 대한간학회
- Cheol-In Kang, "Incidence and Seroprevalence of Hepatitis A Virus Infections among Young Korean Soldiers", Journal of Korean Medical Science, 22(3), pp.546~548 (2007), 대한의학회
- 이정민, "전투 경찰에서 A형 간염 발생률과 항체 양성률", Infection and Chemotherapy, 39(6), pp.292~295 (2007), 대한감염학회
- 권영옥, "부산지역 소아 및 성인의 A형 간염 바이러스 항체 양성률에 대한 역학적 조사", Korean Journal of Pediatrics, 50(4), pp.262~267 (2007), 대한소아과학회
- Yoo HJ, "The clinical feature of acute hepatitis A and IgG anti-HAV seroprevalence of the Busan: Single center experience", Korean J Hepatol, 13(3), pp.S173~ (2007)
- Saab S, "A simple cost-decision analysis model comparing two strategies for hepatitis A vaccination", Am J Med, 109, pp.241~244 (2000)